Pharmaceutical Industry Information Portal

HomeTagsBristol Myers Squibb

All posts by tag

Bristol Myers Squibb

BMS, Merck enter into $2.3 billion partnership with Amphista to discover and develop small molecule protein degraders

Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, May 4th announced a strategic collaboration...

Bristol Myers Squibb sales grew in Q1 due to growth in line products

Pharmaceutical company, drug maker Bristol Myers Squibb on Friday posted slightly higher-than-expected first-quarter earnings thanks to increased sales of its blood-thinning drug Eliquis and...

Nektar Therapeutics and Bristol Myers Squibb stop clinical trials for key cancer drug

Nektar Therapeutics and Bristol Myers Squibb announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination...

FDA approves Bristol Myers’ Opdualag cancer immunotherapy

Bristol Myers Squibb announced that OpdualagTM, a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved by...

U.S FDA approves expanded use of Bristol Myers lung cancer medication

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo®(nivolumab) in combination with platinum-doublet chemotherapy for adult patients with resectable...

Eisai and BMS Enter Into Strategic Collaboration for MORAb-202 Antibody Drug Conjugate

Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses.

Expert Articles